PetCure Oncology reaches 10,000 radiation therapy patients

PetCure Oncology says it has now treated 10,000 pets with radiation therapy since launching in 2015, a milestone the company is framing as evidence that advanced radiation oncology has moved beyond a handful of academic centers and into a broader referral network. In its January 7, 2026 announcement, PetCure and parent network Thrive Pet Healthcare said the growth has been driven by wider availability of stereotactic radiosurgery and stereotactic radiation therapy, which can often be completed in one to three treatments instead of the longer conventional fractionated schedules many practices historically relied on or referred out for. The company has previously reported 8,000 pets treated as of April 2024, underscoring how quickly case volume has expanded. (petcureoncology.com)

Why it matters: For veterinary professionals, the milestone is less about a round number than what it says about referral access, case selection, and client decision-making. PetCure’s model has centered on giving community veterinarians a more practical path to radiation referral, at a time when cancer incidence remains high in companion animals and radiation oncology capacity is still limited. PetCure says there were fewer than 70 traditional veterinary radiation therapy facilities in the U.S. when it was founded, and company leaders have said the field still has only about 100 radiation oncologists worldwide, making access, triage, and collaboration especially important for general practice, surgery, neurology, and medical oncology teams. (petcureoncology.com)

What to watch: Watch for whether PetCure pairs this access narrative with new published outcomes data, additional site expansion, or rollout of newer radiation platforms such as the Sirius system announced for Seattle in early 2026. (empyreanmed.com)